IN2012DN01292A - - Google Patents

Download PDF

Info

Publication number
IN2012DN01292A
IN2012DN01292A IN1292DEN2012A IN2012DN01292A IN 2012DN01292 A IN2012DN01292 A IN 2012DN01292A IN 1292DEN2012 A IN1292DEN2012 A IN 1292DEN2012A IN 2012DN01292 A IN2012DN01292 A IN 2012DN01292A
Authority
IN
India
Prior art keywords
therapy
preparing
processes
compound
formula
Prior art date
Application number
Other languages
English (en)
Inventor
Simon Craig Andrew
Zarah Ismail Salima
Maxwell Lawrence Ronnie
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of IN2012DN01292A publication Critical patent/IN2012DN01292A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IN1292DEN2012 2009-08-27 2010-08-25 IN2012DN01292A (cg-RX-API-DMAC7.html)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23743509P 2009-08-27 2009-08-27
PCT/EP2010/062420 WO2011023733A1 (en) 2009-08-27 2010-08-25 Anhydrate forms of a pyridine derivative

Publications (1)

Publication Number Publication Date
IN2012DN01292A true IN2012DN01292A (cg-RX-API-DMAC7.html) 2015-06-05

Family

ID=42790943

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1292DEN2012 IN2012DN01292A (cg-RX-API-DMAC7.html) 2009-08-27 2010-08-25

Country Status (18)

Country Link
US (1) US8796269B2 (cg-RX-API-DMAC7.html)
EP (1) EP2470545B1 (cg-RX-API-DMAC7.html)
JP (3) JP2013503134A (cg-RX-API-DMAC7.html)
KR (1) KR20120056258A (cg-RX-API-DMAC7.html)
CN (1) CN102639536B (cg-RX-API-DMAC7.html)
AU (1) AU2010288502B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012003435A2 (cg-RX-API-DMAC7.html)
CA (1) CA2772168C (cg-RX-API-DMAC7.html)
DK (1) DK2470545T3 (cg-RX-API-DMAC7.html)
EA (1) EA021411B1 (cg-RX-API-DMAC7.html)
ES (1) ES2440938T3 (cg-RX-API-DMAC7.html)
IL (1) IL217922A (cg-RX-API-DMAC7.html)
IN (1) IN2012DN01292A (cg-RX-API-DMAC7.html)
MX (1) MX2012002369A (cg-RX-API-DMAC7.html)
PL (1) PL2470545T3 (cg-RX-API-DMAC7.html)
SG (1) SG178231A1 (cg-RX-API-DMAC7.html)
WO (1) WO2011023733A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201200812B (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012002369A (es) * 2009-08-27 2012-03-29 Glaxosmithkline Llc Formas de anhidrato de un derivado de piridina.
WO2015200594A2 (en) * 2014-06-25 2015-12-30 Emory University Methods of managing conditioned fear with neurokinin receptor antagonists
CA2984591A1 (en) * 2015-05-18 2016-11-24 Nerre Therapeutics Limited Dual nk-1/nk-3 receptor antagonists for the treatment of sex-hormone-dependent diseases
WO2018109646A1 (en) * 2016-12-15 2018-06-21 Glaxosmithkline Intellectual Property Development Limited Nrf2 compounds
IL276959B2 (en) * 2018-03-14 2024-07-01 Kandy Therapeutics Ltd Novel pharmaceutical formulation comprising dual nk-1/nk-3 receptor antagonists
WO2021030335A1 (en) * 2019-08-12 2021-02-18 Millendo Therapeutics, Inc. A stereoisomerically pure nk-3 receptor antagonist and crystalline forms thereof
US12473260B2 (en) 2019-11-15 2025-11-18 KaNDy Therapeutics Limited Chemical process for making 6-chloro-4-(4-fluoro-2-methylphenyl)pyridin-3-amine a key intermediate of NT-814
EP4431512A1 (en) 2023-03-16 2024-09-18 Bayer Consumer Care AG Novel dual nk-1/nk-3 receptor antagonists
WO2025242584A1 (en) 2024-05-24 2025-11-27 Bayer Consumer Care Ag A stable soft gelatin capsule formulation for elinzanetant
WO2025242583A1 (en) 2024-05-24 2025-11-27 Bayer Consumer Care Ag Novel formulation comprising elinzanetant in a solid dispersion
WO2025242585A1 (en) 2024-05-24 2025-11-27 Bayer Consumer Care Ag Crystalline forms of salts of elinzanetant and compositions containing salts of elinzanetant

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1035115T1 (en) * 1999-02-24 2005-02-28 F. Hoffmann-La Roche Ag 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists
GB0203022D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
KR100700421B1 (ko) * 2003-01-31 2007-03-28 에프. 호프만-라 로슈 아게 2-(3,5-비스-트라이플루오로메틸-페닐)-N-[6-(1,1-다이옥소-1λ6-티오모폴린-4-일)-4-(4-플루오로-2-메틸-페닐)-피리딘-3-일]-N-메틸-아이소부티르아미드의 새로운 결정변형체
KR100744859B1 (ko) * 2003-07-03 2007-08-01 에프. 호프만-라 로슈 아게 정신분열증 치료를 위한 이중 nk1/nk3 길항물질
PL1928886T3 (pl) * 2005-09-09 2011-09-30 Nerre Therapeutics Ltd Pochodne pirydyny i ich zastosowanie w leczeniu zaburzeń psychotycznych
CA2692955A1 (en) * 2007-12-11 2009-07-16 Cipla Ltd A new method for preparation of zopiclone and its polymorphs
GB0814340D0 (en) * 2008-08-05 2008-09-10 Smithkline Beecham Corp Anhydrous crystol form fo a pyridine derivative
MX2012002369A (es) * 2009-08-27 2012-03-29 Glaxosmithkline Llc Formas de anhidrato de un derivado de piridina.
JP6342662B2 (ja) * 2014-01-29 2018-06-13 京セラ株式会社 ドリルおよびそれを用いた切削加工物の製造方法

Also Published As

Publication number Publication date
EA021411B1 (ru) 2015-06-30
KR20120056258A (ko) 2012-06-01
DK2470545T3 (da) 2014-01-13
JP6404186B2 (ja) 2018-10-10
AU2010288502B2 (en) 2013-12-12
EP2470545A1 (en) 2012-07-04
CN102639536B (zh) 2015-03-18
US8796269B2 (en) 2014-08-05
EP2470545B1 (en) 2013-10-09
SG178231A1 (en) 2012-03-29
AU2010288502A1 (en) 2012-02-23
JP2013503134A (ja) 2013-01-31
CA2772168C (en) 2019-01-08
WO2011023733A1 (en) 2011-03-03
CA2772168A1 (en) 2011-03-03
ES2440938T3 (es) 2014-01-31
JP2016000739A (ja) 2016-01-07
EA201270302A1 (ru) 2012-07-30
ZA201200812B (en) 2013-03-27
IL217922A0 (en) 2012-03-29
PL2470545T3 (pl) 2014-03-31
JP2017193564A (ja) 2017-10-26
IL217922A (en) 2016-06-30
MX2012002369A (es) 2012-03-29
CN102639536A (zh) 2012-08-15
BR112012003435A2 (pt) 2016-02-23
US20120157450A1 (en) 2012-06-21

Similar Documents

Publication Publication Date Title
IN2012DN01292A (cg-RX-API-DMAC7.html)
MX2011011661A (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750.
MX2011008864A (es) Tetrahidroazolopirazinas sulfoniladas y su uso como productos medicinales.
NZ608116A (en) Triazine-oxadiazoles
MY149731A (en) Compounds
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
MX2012013274A (es) Novedosos derivados de la pirimidina.
UA109010C2 (en) Morpholino pyrividines and their use in therapy
IN2012DN03182A (cg-RX-API-DMAC7.html)
MX2010002461A (es) (carboxilalquilenfenil)feniloxamidas, metodo para su produccion y uso de las mismas como medicamento.
MX2010002419A (es) (ciclopropilfenil) feniloxamidas, metodo para su produccion y uso como un medicamento.
IN2014CN04530A (cg-RX-API-DMAC7.html)
MY187718A (en) Pharmaceutical formulations
IN2012DN02139A (cg-RX-API-DMAC7.html)
MX2013010898A (es) Novedoso derivados de la pirimidina.
MX2010002210A (es) Derivados de catecolamina y profarmacos de los mismos.
IN2015DN01119A (cg-RX-API-DMAC7.html)
MX2011011776A (es) Nuevos profarmacos de triptolite.
MY160625A (en) Process for preparing pan-cdk inhibitors of the formula(i), and intermediates in the preparation
JO2682B1 (en) Derivatives of alkynil-8.1-naphthayridone, preparations thereof and therapeutic use thereof
MY161749A (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
MX2013006670A (es) Derivado de 2-carboxamida-4-piperazinil-benzofurano.
MX2012007253A (es) Derivados triciclicos y sus usos y composiciones farmaceuticas.
MX2011008126A (es) Compuestos de indol sustituidos como moduladores del receptor 1 de bradiquinina.
IN2012DN02698A (cg-RX-API-DMAC7.html)